

# Minocycline Attenuation Of Rat Corpus Callosum Abnormality Mediated By Low Dose Lipopolysaccharide-induced Microglia Activation

Huangui Xiong (✉ [hxiang@unmc.edu](mailto:hxiang@unmc.edu))

Department of Pharmacology & Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, 68198, USA <https://orcid.org/0000-0003-3450-8876>

Jingdong Zhang

University of Nebraska Medical Center

Ya Zheng

University of Nebraska Medical Center

Jianuo Liu

University of Nebraska Medical Center

Howard S. Fox

University of Nebraska Medical Center

---

## Research

**Keywords:** Lipopolysaccharide, Microglia activation, Neuroinflammation, Corpus callosum dysfunction, Minocycline

**Posted Date:** January 15th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-143613/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

**Background:** Microglia are resident innate immune cells in the brain and the activation of these myeloid cells results in secretion of a variety of proinflammatory molecules, leading to the development of neurodegenerative disorders. Lipopolysaccharide (LPS) is a widely used experimental stimulant in microglia activation. We have previously shown that LPS produced microglia activation and evoked detectable functional abnormalities in rat corpus callosum (CC) *in vitro*. Here, we further examined the effects of low dose LPS-induced microglia activation and resultant white matter abnormality in the CC *in vivo* and its attenuation by an anti-inflammatory agent minocycline.

**Methods:** Twenty-four SD rats were divided randomly into three groups and intra-peritoneally injected daily with saline, LPS and LPS+minocycline, respectively. All animals were subject to MRI tests 6 days post injection. The animals were then sacrificed for harvest the CC tissues for electrophysiology, Western blotting, and immunocytochemistry. One-way ANOVA with Tukey's posttest of all pair of columns was employed statistical analyses.

**Results:** Systemic administration of LPS produced microglial activation in the CC as illustrated by Iba-1 immunofluorescent staining. We observed that a large number of Iba-1 positive microglial cells were hyper-ramified with hypertrophic somata or even amoeba like in the LPS-treated animals and such changes were significantly reduced by co-administration of minocycline. Electrophysiological recordings of axonal compound action potential (CAP) revealed an impairment on the CC functionality as detected by a reduction on CAP magnitude. Such an impairment was supported by a reduction on fast axonal transportation evidenced by  $\beta$ -amyloid precursor protein accumulation. These alterations were attenuated by minocycline, demonstrating minocycline reduction of microglia-mediated interruption of white matter integrity and function in the CC.

**Conclusions:** Systemic administration of LPS produced microglia activation in the CC and resultant functional abnormalities that were attenuated by an anti-inflammatory agent minocycline.

## Background

Microglia are resident innate immune cells in the central nervous system (CNS) [1, 2] and have diverse functions in the brain under normal and disease conditions. They are involved in the immunity, neurogenesis, synaptogenesis, neurotrophic support, removal of cellular/tissue debris and maintaining CNS homeostasis [3]. Microglia appear as ramified cells in the resting condition and change their shape to an amoeboidic form once activated. Ample evidence indicate that microglia are one of the major cell types involved in the inflammatory responses in the CNS. The activated microglia release a variety of pro-inflammatory molecules including, but are not limited to, chemokines, cytokines, cyclooxygenase-2, inducible nitric oxide synthase and nitric oxide. These substances provoke inflammatory responses and brain tissue damage that contribute to the pathogenesis of neurodegenerative disorders including, but not

limited to, Alzheimer's disease [4–8], Parkinson's disease [9, 10] and human immunodeficiency virus type 1(HIV-1)-associated neurocognitive disorders [11, 12].

Many bioactive substances and factors can induce microglial cell activation. Lipopolysaccharide (LPS, a bacterial endotoxin) is the most commonly used pro-inflammatory stimulus for microglia both *in vitro* and *in vivo*. It is well-established that LPS-associated neuropathology stems from the microglia activation and resultant release of cytokines and inflammatory mediators [13–16]. We have previously shown that LPS, at low doses, produced microglia activation in rat corpus callosum (CC) *in vitro* and evoked detectable functional abnormalities on white matter tracts in the absence of overt axonal injury, hypoxia and trauma that could be detrimental to the white matter [17]. Those findings imply that suppression of microglia activation in the CC by anti-inflammatory reagents may have a therapeutic benefit in protecting white matter tracts from inflammatory assault.

Ample evidence indicate that minocycline (7-dimethylamino-6-dimethyl-6-deoxytetracycline), a second-generation semisynthetic tetracycline analogue, has a neuroprotective capacity in various animal studies. It is a highly lipophilic molecule that can easily penetrate the blood-brain barrier [18], thus promoting its accumulation in the CNS and enabling its use in the treatment of neurodegenerative diseases [19, 20]. Furthermore, there is rapidly growing evidence indicating that minocycline may exert its neuroprotective activity through suppression of microglial activation[21], inhibition of neuroinflammatory response and attenuation of neuronal apoptosis [22–24]. These actions appear significantly different from its antibiotic properties. Indeed, minocycline attenuated brain white matter injuries induced by intracerebral hemorrhage or cerebral ischemia through its anti-inflammatory activity [25–27]. In the present study we examined protective effects of minocycline on the rat CC abnormalities induced by low-dose LPS. Our results showed that systemic administration of LPS produced microglial activation in the CC and impaired CC functionality as revealed by reduction on axonal compound action potential (CAP) magnitude and fast axonal transportation evidenced by  $\beta$ -amyloid precursor protein ( $\beta$ -APP) accumulation. These alterations were attenuated by minocycline, demonstrating minocycline reduction of microglia-mediated interruption of white matter functionality in the CC of rat.

## Materials And Methods

### Animals

Twenty-four adult Sprague–Dawley rats (40–50 days old; 12 male and 12 female) were used and they were divided into 3 groups, each with 4 male and 4 female animals. Group 1 received sterilized saline injection as a control (Saline group), LPS was injected to group 2 rats (LPS group) and the 3rd group received both LPS and minocycline injection (LPS + Minocycline). All experimental protocols and animal care were carried out in accordance with the National Institutes of Health *Guide for the Care of Laboratory Animals in Research* and approved by the Institutional Animal Care and Use Committee of the University of Nebraska Medical Center. All efforts were made to minimize animal suffering and the number of animals used in this study.

## Intraperitoneal Injection of Saline, LPS and LPS + Minocycline

LPS (*Escherichia coli*, L2880, Sigma, St Louis, MO) was prepared with saline at 1 mg/ml and stored at -20°C. Minocycline hydrochloride (M9511, Sigma) was dissolved in saline at 25 mg/ml shortly before administration. LPS of 1 mg/kg was intra-peritoneally (*i.p.*) injected daily in LPS group animals and animals in saline group received equivalent volume of saline daily for three consecutive days. In LPS + Minocycline group, minocycline of 25 mg/kg was *i.p.* administered daily 2 hours before LPS injection for four consecutive days.

## Magnetic Resonance Imaging

All animals in three groups received MRI tests at the 6th day after initial injection. The MRI tests were performed on a 7T/21 cm MR scanner (Bruker, Karlsruhe, Germany) equipped with Resonance Research (Billerica, MA) gradients and shims. Animals were anesthetized with a 2% isoflurane/oxygen mixture and body temperatures were kept constant at 37°C with a MRI-compatible heater (SAll, NY). T<sub>2</sub>-weighted anatomical images were acquired from 16 contiguous coronal slices with a rapid acquisition with relaxation enhancement sequence. For each animal, an average diffusion-weighted image volume including fractional anisotropy (FA) and mean diffusivity (MD) was reconstructed. To measure the diffusion indices quantitatively, Regions-of-Interest (ROI, Fig. 1A, red and green frames) were drawn manually from the raw FA maps of each rat. The average FA and MD values from measurement in the ROIs were calculated and compared among the saline, LPS and LPS + Minocycline injection groups. In addition, the FA and MD values of 4 male and 4 female rats from the same group were statistically compared in each group.

## Preparation of CC slices and Electrophysiology

On the day immediately after MRI tests, six animals (3 male /3 female) from each group were deeply anesthetized with isoflurane and then decapitated. Brains were quickly dissected out of the cranial cavities, placed into an ice-cold (4 °C) oxygenated artificial cerebrospinal fluid (ACSF) and cut into 500 µm (in thickness) slices as previously described [28]. Every other slice was used to perform extraction of protein for Western blot. In addition, two slices containing rostral and middle part of the CC body, respectively, were directly transferred into 4% paraformaldehyde in 1X phosphate buffered saline (PBS, pH 7.4) to be fixed for immunofluorescent staining. The remaining slices were used for electrophysiology recordings. The CC fiber CAPs were evoked by constant current (0.1–0.5 mA, 40 µs in duration, 0.2 Hz) via a bipolar tungsten stimulating electrode. The recording electrodes, made from borosilicate glass capillaries (1.5/0.84 OD/ID, WPI, Sarasota, FL) and filled with 2M NaCl (impedance 1–4 MΩ), were placed 1-1.5 mm away from the stimulating site. Signals were amplified through an Axopatch 1D amplifier (Molecular Devices, San Jose, CA) and a Dagan EX4-400 amplifier (Dagan Corp., Minneapolis, MN), filtered at 1 kHz, digitized at 5 kHz with Digidata 1440A interface (Molecular Devices) and recorded on a Dell computer with pCLAMP 10.1 software (Molecular Devices).

## Western Blot

The CC white matter tissues were dissected from the other half of the slices mentioned above in cold ACSF under an anatomic microscope. Then, the CC tissue was quickly transferred into Tissue Extraction Reagent 1 (FNN0071, Invitrogen, Camarillo CA) with 1:1000 protease inhibitor (P-2714, Sigma) and homogenized. Protein concentration was measured by bicinchoninic acid assay (BCA assay). Routine electrophoresis was carried out using 10% sodium dodecyl sulfate-polyamide gel. Polyclonal rabbit anti- $\beta$ -APP (1:600; AB5302, Millipore, Temecula CA), monoclonal mouse anti-inducible nitric oxide synthase (iNOS; 1:500; AB49999, Abcam, Cambridge MA) and rabbit anti-tumor necrosis factor alpha (TNF- $\alpha$ ; 1:1000; AB66579, Abcam) were used to identify  $\beta$ -APP, iNOS and TNF- $\alpha$ . Mouse anti- $\beta$ -actin (1:10000; Sigma, #A2228) was applied as a gel loading control. Immunoreactivity bands were detected using enhanced chemiluminescence and developed with autoradiography film.

## Immunocytochemistry

1. *Immunofluorescent staining* Total 6 rats, two (a male and a female) from each group, were euthanized with isoflurane and transcardially perfused with saline followed by 4% paraformaldehyde in 1X PBS. The brains were removed and cryo-protected by gradient sucrose. Similarly, the two freshly fixed CC slices mentioned above were undergone cryo-protection as well. Then, coronal sections was cut at 10  $\mu$ m thickness and mounted on slides immediately. About 10% sections containing CC was selected to conduct immunofluorescent staining and intensity analysis. Sections were immunoblocked routinely and incubated with rabbit anti-ionizing calcium binding adaptor protein-1 (Iba-1; 1:300; Wako Chemicals USA Inc, Richmond VA), monoclonal rat anti-myelin basic protein (MBP; 1:200; Abcam) and polyclonal rabbit anti-neurofilament (NF; 1:400; Millipore) at room temperature overnight. Alexa Fluor 488 conjugated anti-rabbit antibodies (1:500; Molecular Probes, CA) were used for immunofluorescent visualization of microglia and nerve fibers. Control sections were stained in the same way without primary antibody.
2. *Proportional area and immunostaining intensity measurements* Microimages for proportional area measurement were acquired through 20X lens and measurement was performed by using SlideBook (6.0.10; Intelligent Imaging Innovations Inc., Denver, CO). Iba-1 labeling was masked as selected area at first and the whole CC area in scope field, excluding area of lateral ventricle if any, was masked as measured area that will be a denominator. Immunofluorescence intensity of MBP and NF were also collected and quantified using SlideBook. Likewise, images were acquired through 20X lens, the positive MBP or NF labeling was masked and the intensity was scaled, and the measured whole nerve bundle was masked as a denominator; then, those values were statistically analyzed and compared.

## Statistical Analysis

FA and MD values were processed with One-way ANOVA with Tukey's posttest of all pair of columns. One-way ANOVA analysis of the area under the curve (AUC), with Tukey's posttest of all pair of columns, was used to test differences between Input-Output (I/O) curves of CAPs recorded from aforementioned three groups. Proportional area for Iba-1 staining, MBP or NF immunoreactivity intensities and protein density

of  $\beta$ -APP, iNOS and TNF- $\alpha$  from aforementioned three groups were also statistically compared with One-way ANOVA with Tukey's posttest of all pair of columns. Statistics were processed by using GraphPad Prism 5 (GraphPad Software Inc. La Jolla, CA) and significance level was indicated as  $p < 0.05$  and  $p < 0.01$ , represented by "\*" and "\*\*" respectively.

## Results

### **Disturbance of white matter linear integrity by LPS, partially rescued by Minocycline**

The measurement and analysis were focused on rostral and middle CC regions, and fractional anisotropy was measured through the map (Fig. 1A); while mean diffusivity was calculated by using measured  $\lambda_L$  and  $\lambda_T$  parameters. FA reflects linear movements of water molecules and MD, in contrary, suggests a free diffusion of water and the extent of freedom {Le Bihan, 2001 #10291. Comparison between Saline, LPS and LPS + Minocycline groups by one-way ANOVA showed that water linear movement was significantly distorted (Fig. 1B;  $p < 0.05$ ) by system LPS and minocycline could reverse this distortion to an approximately significant level ( $p = 0.0657$ ). ANOVA comparison of MD between Saline, LPS and LPS + Minocycline groups exhibited that LPS injection enhanced water diffusion almost to a significant level comparing to the Saline injection did (Fig. 1C;  $p = 0.0570$ ); while, pre-delivery of minocycline appeared to attenuate this effect (Fig. 1C). In addition, comparison of FA and MD values between male and female rats within the same group, namely in the Saline, LPS and LPS + Minocycline groups, showed no evident difference.

### **Declination of CC nerve fibers CAP by LPS, significantly inverted by Minocycline**

CAPs were recorded in response to increment increase of stimulating intensities and their amplitudes were measured and plotted as corresponding input-output (I/O) curve (Fig. 2). One-way ANOVA analysis of AUC displayed delivery of LPS highly significantly downshifted I/O curve versus Saline group (Fig. 2A;  $p < 0.01$ ). This result suggests a functional impairment of white matter tract following system LPS. In addition, ANOVA statistical comparison of AUC values from LPS group with that of LPS + Minocycline group showed minocycline significantly reversed the adverse effect of LPS on CAP (Fig. 2B;  $p < 0.05$ ), reflecting a protection of minocycline for white matter function against LPS induced impairment.

### **Minocycline reversed high densities of iNOS and TNF- $\alpha$ induced by LPS**

Protein densities of  $\beta$ -APP, iNOS, TNF- $\alpha$  and  $\beta$ -actin were measured and normalized by corresponding  $\beta$ -actin level in each sample. The densities of  $\beta$ -APP and iNOS in CC tissues of LPS injection group were significantly enhanced comparing to that in saline group (Fig. 3A and B;  $p < 0.01$ ). The TNF- $\alpha$  level was significantly higher in the LPS group than that in saline group (Fig. 3C). In contrast, co-injection with

minocycline significantly reversed the LPS evoked iNOS and TNF- $\alpha$  upregulation (Fig. 3B and C,  $p < 0.05$ ), but not  $\beta$ -APP accumulation in the CC (Fig. 3A). Nonetheless, the impairment on fast axon transportation was ameliorated by co-delivery of minocycline.

## LPS Activation of microglia and its attenuation by Minocycline

Resting microglia with thin somata and delicate pseudopodia were observed in the CC of saline group as revealed by Iba-1 immunofluorescent staining (Fig. 4A and inset). A large number of Iba-1 positive microglia were hyper-ramified with hypertrophic somata or even amoeba like (Fig. 4B and inset) in the LPS group. When minocycline was co-administrated with LPS, microglia with amoeba like appearance became much fewer, and hypertrophic pseudopodia and/or mild hypertrophic soma were also observed (Fig. 4C and inset). Proportional area values {Donnelly, 2009 #88} were calculated by normalizing selected-area with the whole measured-area. ANOVA analysis indicated a highly significant morphological change evoked by system LPS comparing to that from saline group (Fig. 4D;  $p < 0.01$ ). Such morphological changes were significantly attenuated by co-administration of minocycline (Fig. 4D;  $p < 0.05$ ).

## Activation of microglia on white matter fiber integrity

Densities of MBP and NF reflect white matter tract integrity. The MBP primarily signifies myelinated nerve fibers and the NF reflects integrity of both myelinated and unmyelinated fibers [29, 30]. To examine if injection of LPS injures white matter fibers, we measured intensity of immunofluorescence that labels MBP (Fig. 5A-C) and NF (E-G), digitized their densities and then normalized by the whole area of measured nerve fibers in the CC. Statistic analyses showed no significant difference between saline, LPS and LPS + Minocycline groups (Fig. 5D and H), indicating no significant damage on myelinated nerve fibers after administration of LPS. However, the intensity of NF labeling in the LPS group did exhibit somewhat decrease which was reversed by minocycline (Fig. 5H), implying some adverse effect of microglia activation on NF transportation and assembly.

## Discussion

Using LPS to induce microglia activation *ex vivo*, we have previously demonstrated that conditioned microglia activation in rat CC resulted in white matter tract malfunction as illustrated by a reduction of CAP magnitude and an impairment of fast axon transport reflected by accumulation of  $\beta$ -APP [17]. The extent of microglia activation was correlated to the alterations of CAP and fast axon transport of  $\beta$ -APP. Based on our previous experimental results [17] and the findings by others [31, 32], we further investigated and compared, using an *in vivo* semi-quantification test, the extent of white matter tract abnormalities with the states of microglia activation, focusing on the CC region. Our results showed that microglia activation induced by systemic administration of LPS produced white matter tract malfunction

in the CC and minocycline, a semisynthetic tetracycline derivative, attenuated LPS-induced microglia activation and resultant white matter abnormalities in the CC.

Increasing evidence indicate that neuroinflammation provoked by microglia activation plays an important role in the pathogenesis of neurological disorders [6–12]. Using LPS to mimic an etiological factor to induce microglial activation in many neurological disorders is widely used in animal studies [33–35]. It has been shown that LPS at a dose of 1 mg/kg/day through *i.p.* delivery was not possible to impair blood brain barrier and enter the brain freely [33, 34]. In contrast, three consecutive deliveries were able to effectively activate microglia and fully activation was observed at the third day after systemic delivery [31, 32]. Using a three-day delivery protocol we did observe microglia activation and functional impairment in the CC. Our results were in a fully agreement with those observations made by others [31, 32].

In a recent study, the authors reported that systemic delivery of LPS for 3 days resulted in a significant malfunction of hippocampus and the CC nerve fibers with robust microglia activation in both brain regions [31]. Three days post LPS delivery, hippocampal function largely recovered with a reduced microglia activation, while the CC nerve fibers malfunction exacerbated [31]. Their results were in consistent with a prior report that activation of microglia was detected 8–24 h after systemic LPS delivery and explicit morphological change was visualized at the 3rd day following 1 or 2.5 mg/kg LPS injection [32]. Noteworthy, comparison of microglia activation levels in the CC with that in the hippocampus at that time point showed a significant higher in the CC than that in hippocampus [31].

In the present work, we adopted a similar procedure to evoke microglia activation as employed by other researchers [31, 32] and examined potential alterations on white matter integrity and function in the CC. We observed that systemic administration of LPS induced microglia activation as determined by labeling Iba-1 positive microglial cells and the morphological changes as measured and assessed using a proportional area comparison [36, 37]. LPS-induced microglia activation was supported by elevated expression levels of inflammatory markers, such as iNOS and TNF- $\alpha$ . The observed changes associated with LPS-stimulated microglia activation include: **1)** an interruption of the CC fibers linear integrity detected by diffusion tensor magnetic resonance imaging (DT-MRI), which can map movements of water molecules and image linear integrity of the white matter tract [38]; **2)** a reduction on magnitude of electrical evoked axonal CAPs, implying for a functional change of the white matter tracts [17, 31]; **3)** an accumulation of  $\beta$ -APP (which travels along axons through fast axon transportation), a well-accepted marker for white matter tracts injury [39, 40]. These alterations were partially rescued or significantly reversed by administration of minocycline. Besides, we analyzed the expression levels of myelin basic protein (MBP) and neurofilament (NF) by immunostaining and found no significant change on MBP and slightly reduction of NF, suggesting that degeneration or demyelination of nerve fibers was not ensued in the time course adopted in this study.

How systemically administered LPS enters the brain is not fully understood. A study using radiocarbon labeled LPS to examine how the LPS passes blood brain barrier (BBB) demonstrated that binding to LPS

receptors on endothelium membrane is probably the predominant pathway through which the LPS enters the brain parenchyma [33]. The LPS might bind to endothelial CD14 (cluster of differentiation 14) and/or toll-like receptors (TLR) 4 and 2 to cross the BBB, as expression levels of endothelial CD14 mRNAs were up-regulated shortly after LPS injection and overexpression of TLR mRNAs lasted for a longer time [33]. Epithelial cells of the choroid plexus also express CD14 and their mRNAs in the epithelium were significantly elevated for much longer time than in BBB endothelium following system LPS treatment [41]. Moreover, significant increment of pro-inflammatory immune cells crossing choroid plexus into the cerebrospinal fluid (CSF) is observed after system LPS [42, 43]. These reports imply the first delivery of LPS might ensue a little amount of LPS into the brain parenchyma. This implication was supported by experimental results that the concentration of LPS in the brain parenchyma was only 0.025% of the circulating LPS following a single injection of doses from 0.1 to 5 mg/kg [34]. In addition, the first cytokine released into the circulation after stimulation of the immune system with LPS was TNF- $\alpha$  [44], suggesting that TNF- $\alpha$  might be the first pro-inflammatory cytokine entering the brain from the circulation following systemic LPS. However, a study in rats using isotope labeled TNF- $\alpha$  to monitor the rate of its crossing the BBB in both physiological condition and systemic LPS unveiled no significant change in up-taking rate for isotope labeled TNF- $\alpha$  between 4 and 24 h after administration (*i.p.*) of LPS [45]. TNF receptors 1 and 2 on BBB endothelium transport TNF- $\alpha$  crossing BBB whenever the BBB is intact [46, 47] and their mRNA expression levels in the endothelium were up-regulated following LPS treatment but their receptor proteins exhibited no significant increase [45]. This paradox may explain why no significant change in up-taking rate for isotope labeled TNF- $\alpha$  was detected after administration (*i.p.*) of LPS [45].

In light of aforementioned studies, we assume that: **1)** the first LPS injection might prime resident microglia through limited amount of LPS and TNF- $\alpha$  entrance into the brain from circulation. The microglia in the CC immediately adjacent to the ventricles might be activated in an earlier time fashion, considering the pro-inflammatory monocytes, granulocytes and lymphocytes in the CSF are significantly increased [42, 43]. **2)** the second injection of LPS might activate most of microglia and the third delivery further challenged microglia, leading to production of significant amount of pro-inflammatory cytokines including TNF- $\alpha$ , as reflected by our western blot results. **3)** microglia were eventually agitated to become neurotoxic because up-regulated iNOS expression, as revealed by our western blot results, is a sign for detrimental microglia activation [48, 49]. In this case, the observed malfunction of the white matter tract was most likely due to activated microglia since our proportional area measurement of Iba-1 immunoreactivity [37] displayed a positive correlation between microglia activation and severity of white matter malfunction. The direct adverse effect of LPS and/or circulating TNF- $\alpha$  on white matter tract, if any, could be ignorable.

It has been shown that systemic administration of LPS and over activated microglia affected both grey matter in the hippocampus and white matter in the CC, with prolonged adverse effect on the CC [31]. The mechanism underlying such a difference is still unclear. Based on our recent findings that microglia pseudopodia directly contact node of Ranvier or node like sodium channel clusters on the CC nerve fibers, it might be possible that activation of microglia changed the contacting ratio and pattern between pseudopodia and node like structures [50]. In addition, large CC area abutting to CSF in the ventricles may

facilitate interaction between pro-inflammatory substances in the CSF and the microglia on the CC border [42, 43]. Nevertheless, the present *in vivo* studies demonstrated that activation of microglia had a noxious effect in the CC. Such effect might be ensued as a significant increment of iNOS, an established sign for detrimental microglia activation [48, 49]. In parallel, malfunction of the CC nerve fibers was reflected by interruption of fiber bundle linear integrity as detected by DT-MIR, reduction of CC nerve fibers CAP magnitude and accumulation (decelerated transportation) of  $\beta$ -APP through axons in the CC.

## Conclusions

Systemic administration of LPS induced microglia activation in the CC of rat, resulting in morphological and physiological alterations that were ameliorated or reverted by minocycline, a well-characterized anti-inflammatory agent. As white matter injury has been detected in Alzheimer's disease [51–53], Parkinson's disease [54, 55] and HIV-associated dementia [56–58], the LPS-induced microglia activation and resultant white matter abnormalities may represent an exemplary mechanism for the pathogenesis of neurodegenerative disorders. Thus, the amelioration or revert of activated microglia-induced white matter abnormalities by minocycline implies a therapeutic potential for aforementioned neurological diseases.

## Abbreviations

ACSF  
artificial cerebrospinal fluid; BBB: blood brain barrier; CAP: compound action potential; CC: corpus callosum; CNS: central nervous system; CSF: cerebrospinal fluid; FA: fractional anisotropy; HIV-1: human immunodeficiency virus type 1; i.p.: intraperitoneally; LPS: Lipopolysaccharide; MBP: myelin basic protein; MD: mean diffusivity; NF: neurofilament; ROI: Regions-of-Interest; TLR: toll-like receptors.

## Declarations

### Acknowledgements

We warmly thank Dr. Judith Strong (Faculty of University of Cincinnati Medical Center) for her scientific comments and recommendation on choosing statistical method.

### Author Contributions

J.Z., H.X. directed study, interpreted the results and wrote the manuscript; J.Z., M.B., J. L., performed experiments and collected/analyzed data; Y.Z., analyzed data partially and revised manuscript; H.X., H.S.F. provided funding for the study. All authors, except M.B. (who passed away in an accident), read and approved the manuscript.

### Funding

This study was supported by NIH grants R01 NS077873, R01DA050540 (H.X.) and P30 MH062261 (H.S.F.).

### **Availability of data and materials**

The data that support the findings of this study are available from co-corresponding authors upon reasonable request.

### **Ethics approval and consent to participate**

All experimental protocols and animal care were carried out in accordance with the National Institutes of Health *Guide for the Care of Laboratory Animals in Research* and approved by the Institutional Animal Care and Use Committee of the University of Nebraska Medical Center (IACUC # 19-085-07-FC).

### **Consent for publication**

Not applicable

### **Competing Interests**

The authors declare that they have no competing of interests.

## **References**

1. Graeber MB: **Changing face of microglia.***Science* 2010, **330**:783-788.
2. Bilimoria PM, Stevens B: **Microglia function during brain development: New insights from animal models.***Brain Res* 2015, **1617**:7-17.
3. Augusto-Oliveira M, Arrifano GP, Lopes-Araujo A, Santos-Sacramento L, Takeda PY, Anthony DC, Malva JO, Crespo-Lopez ME: **What Do Microglia Really Do in Healthy Adult Brain?***Cells* 2019, **8**.
4. Wojtera M, Sobow T, Kloszewska I, Liberski PP, Brown DR, Sikorska B: **Expression of immunohistochemical markers on microglia in Creutzfeldt-Jakob disease and Alzheimer's disease: morphometric study and review of the literature.***Folia Neuropathol* 2012, **50**:74-84.
5. Hansen DV, Hanson JE, Sheng M: **Microglia in Alzheimer's disease.***J Cell Biol* 2018, **217**:459-472.
6. Hopperton KE, Mohammad D, Trepanier MO, Giuliano V, Bazinet RP: **Markers of microglia in post-mortem brain samples from patients with Alzheimer's disease: a systematic review.***Mol Psychiatry* 2018, **23**:177-198.
7. Anwar S, Rivest S: **Alzheimer's disease: microglia targets and their modulation to promote amyloid phagocytosis and mitigate neuroinflammation.***Expert Opin Ther Targets* 2020, **24**:331-344.
8. Hemonnot AL, Hua J, Ulmann L, Hirbec H: **Microglia in Alzheimer Disease: Well-Known Targets and New Opportunities.***Front Aging Neurosci* 2019, **11**:233.

9. Lazdon E, Stoloro N, Frenkel D: **Microglia and Parkinson's disease: footprints to pathology.***J Neural Transm (Vienna)* 2020, **127**:149-158.
10. Yao YY, Ling EA, Lu D: **Microglia mediated neuroinflammation - signaling regulation and therapeutic considerations with special reference to some natural compounds.***Histol Histopathol* 2020:18239.
11. Wallet C, De Rovere M, Van Assche J, Daouad F, De Wit S, Gautier V, Mallon PWG, Marcello A, Van Lint C, Rohr O, Schwartz C: **Microglial Cells: The Main HIV-1 Reservoir in the Brain.***Front Cell Infect Microbiol* 2019, **9**:362.
12. Katuri A, Bryant J, Heredia A, Makar TK: **Role of the inflammasomes in HIV-associated neuroinflammation and neurocognitive disorders.***Exp Mol Pathol* 2019, **108**:64-72.
13. Hoogland ICM, Westhoff D, Engelen-Lee JY, Melief J, Valls Seron M, Houben-Weerts J, Huitinga I, van Westerloo DJ, van der Poll T, van Gool WA, van de Beek D: **Microglial Activation After Systemic Stimulation With Lipopolysaccharide and Escherichia coli.***Front Cell Neurosci* 2018, **12**:110.
14. Gao X, He D, Liu D, Hu G, Zhang Y, Meng T, Su Y, Zhou A, Huang B, Du J, Fu S: **Beta-naphthoflavone inhibits LPS-induced inflammation in BV-2 cells via AKT/Nrf-2/HO-1-NF-kappaB signaling axis.***Immunobiology* 2020, **225**:151965.
15. Lelakova V, Beraud-Dufour S, Hosek J, Smejkal K, Prachyawarakorn V, Pailee P, Widmann C, Vaclavik J, Coppola T, Mazella J, et al: **Therapeutic potential of prenylated stilbenoid macasiamenene F through its anti-inflammatory and cytoprotective effects on LPS-challenged monocytes and microglia.***J Ethnopharmacol* 2020, **263**:113147.
16. Li XW, He RZ, Li Y, Ruan ZF: **Tizoxanide mitigates inflammatory response in LPS-induced neuroinflammation in microglia via restraining p38/MAPK pathway.***Eur Rev Med Pharmacol Sci* 2020, **24**:6446-6454.
17. Yang X, Zhang JD, Duan L, Xiong HG, Jiang YP, Liang HC: **Microglia activation mediated by toll-like receptor-4 impairs brain white matter tracts in rats.***J Biomed Res* 2018, **32**:136-144.
18. Brogden RN, Speight TM, Avery GS: **Minocycline: A review of its antibacterial and pharmacokinetic properties and therapeutic use.***Drugs* 1975, **9**:251-291.
19. Kielian T, Esen N, Liu S, Phulwani NK, Syed MM, Phillips N, Nishina K, Cheung AL, Schwartzman JD, Ruhe JJ: **Minocycline modulates neuroinflammation independently of its antimicrobial activity in staphylococcus aureus-induced brain abscess.***Am J Pathol* 2007, **171**:1199-1214.
20. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM: **The promise of minocycline in neurology.***Lancet Neurol* 2004, **3**:744-751.
21. Huang J, Liu G, Shi B, Shi G, He X, Lu Z, Zheng J, Zhang H, Chen H, Zhu Z: **Inhibition of microglial activation by minocycline reduced preoligodendrocyte injury in a neonatal rat brain slice model.***J Thorac Cardiovasc Surg* 2018, **156**:2271-2280.
22. Cankaya S, Cankaya B, Kilic U, Kilic E, Yulug B: **The therapeutic role of minocycline in Parkinson's disease.***Drugs Context* 2019, **8**:212553.
23. Choi Y, Kim HS, Shin KY, Kim EM, Kim M, Kim HS, Park CH, Jeong YH, Yoo J, Lee JP, et al: **Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease**

- models. *Neuropsychopharmacology* 2007, **32**:2393-2404.**
24. Stirling DP, Khodarahmi K, Liu J, McPhail LT, McBride CB, Steeves JD, Ramer MS, Tetzlaff W: **Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury.** *J Neurosci* 2004, **24**:2182-2190.
  25. Yang H, Gao XJ, Li YJ, Su JB, E TZ, Zhang X, Ni W, Gu YX: **Minocycline reduces intracerebral hemorrhage-induced white matter injury in piglets.** *CNS Neurosci Ther* 2019, **25**:1195-1206.
  26. Du B, Li H, Zheng H, Fan C, Liang M, Lian Y, Wei Z, Zhang Y, Bi X: **Minocycline Ameliorates Depressive-Like Behavior and Demyelination Induced by Transient Global Cerebral Ischemia by Inhibiting Microglial Activation.** *Front Pharmacol* 2019, **10**:1247.
  27. Faheem H, Mansour A, Elkordy A, Rashad S, Shebl M, Madi M, Elwy S, Niizuma K, Tominaga T: **Neuroprotective effects of minocycline and progesterone on white matter injury after focal cerebral ischemia.** *J Clin Neurosci* 2019, **64**:206-213.
  28. Oh SW, Shin NY, Choi JY, Lee SK, Bang MR: **Altered White Matter Integrity in Human Immunodeficiency Virus-Associated Neurocognitive Disorder: A Tract-Based Spatial Statistics Study.** *Korean J Radiol* 2018, **19**:431-442.
  29. Chang EH, Argyelan M, Aggarwal M, Chandon TS, Karlsgodt KH, Mori S, Malhotra AK: **The role of myelination in measures of white matter integrity: Combination of diffusion tensor imaging and two-photon microscopy of CLARITY intact brains.** *Neuroimage* 2017, **147**:253-261.
  30. Mages B, Aleithe S, Altmann S, Blietz A, Nitzsche B, Barthel H, Horn AKE, Hobusch C, Hartig W, Krueger M, Michalski D: **Impaired Neurofilament Integrity and Neuronal Morphology in Different Models of Focal Cerebral Ischemia and Human Stroke Tissue.** *Front Cell Neurosci* 2018, **12**:161.
  31. Zhang J, Li A, Song Z: **Systemic LPS resulted in a transient hippocampus malfunction but a prolonged corpus callosum injury.** *BMC Anesthesiol* 2017, **17**:105.
  32. Buttini M, Limonta S, Boddeke HW: **Peripheral administration of lipopolysaccharide induces activation of microglial cells in rat brain.** *Neurochem Int* 1996, **29**:25-35.
  33. Singh AK, Jiang Y: **How does peripheral lipopolysaccharide induce gene expression in the brain of rats?** *Toxicology* 2004, **201**:197-207.
  34. Banks WA, Robinson SM: **Minimal penetration of lipopolysaccharide across the murine blood-brain barrier.** *Brain Behav Immun* 2010, **24**:102-109.
  35. Inoue T, Yamakage H, Tanaka M, Kusakabe T, Shimatsu A, Satoh-Asahara N: **Oxytocin Suppresses Inflammatory Responses Induced by Lipopolysaccharide through Inhibition of the eIF-2-ATF4 Pathway in Mouse Microglia.** *Cells* 2019, **8**.
  36. Streit WJ, Walter SA, Pennell NA: **Reactive microgliosis.** *Prog Neurobiol* 1999, **57**:563-581.
  37. Donnelly DJ, Gensel JC, Ankeny DP, van Rooijen N, Popovich PG: **An efficient and reproducible method for quantifying macrophages in different experimental models of central nervous system pathology.** *J Neurosci Methods* 2009, **181**:36-44.

38. Le Bihan D, Mangin JF, Poupon C, Clark CA, Pappata S, Molko N, Chabriat H: **Diffusion tensor imaging: concepts and applications.***J Magn Reson Imaging* 2001, **13**:534-546.
39. Buxbaum JD, Thinakaran G, Koliatsos V, O'Callahan J, Slunt HH, Price DL, Sisodia SS: **Alzheimer amyloid protein precursor in the rat hippocampus: transport and processing through the perforant path.***J Neurosci* 1998, **18**:9629-9637.
40. Medana IM, Esiri MM: **Axonal damage: a key predictor of outcome in human CNS diseases.***Brain* 2003, **126**:515-530.
41. Lacroix S, Feinstein D, Rivest S: **The bacterial endotoxin lipopolysaccharide has the ability to target the brain in upregulating its membrane CD14 receptor within specific cellular populations.***Brain Pathol* 1998, **8**:625-640.
42. Boiesen M, Freudenberg MA, Bog-Hansen TC, Galanos C: **Appearance of white blood cells in the cerebrospinal fluid of rats following intravenous injection of lipopolysaccharide.***Acta Neurol (Napoli)* 1991, **13**:87-96.
43. Endo H, Sasaki K, Tonosaki A, Kayama T: **Three-dimensional and ultrastructural ICAM-1 distribution in the choroid plexus, arachnoid membrane and dural sinus of inflammatory rats induced by LPS injection in the lateral ventricles.***Brain Res* 1998, **793**:297-301.
44. Beutler B, Cerami A: **The biology of cachectin/TNF—a primary mediator of the host response.***Annu Rev Immunol* 1989, **7**:625-655.
45. Osburg B, Peiser C, Domling D, Schomburg L, Ko YT, Voigt K, Bickel U: **Effect of endotoxin on expression of TNF receptors and transport of TNF-alpha at the blood-brain barrier of the rat.***Am J Physiol Endocrinol Metab* 2002, **283**:E899-908.
46. Madge LA, Pober JS: **TNF signaling in vascular endothelial cells.***Exp Mol Pathol* 2001, **70**:317-325.
47. Pan W, Kastin AJ: **TNFalpha transport across the blood-brain barrier is abolished in receptor knockout mice.***Exp Neurol* 2002, **174**:193-200.
48. Saha RN, Pahan K: **Regulation of inducible nitric oxide synthase gene in glial cells.***Antioxid Redox Signal* 2006, **8**:929-947.
49. Brown GC, Neher JJ: **Inflammatory neurodegeneration and mechanisms of microglial killing of neurons.***Mol Neurobiol* 2010, **41**:242-247.
50. Zhang JD, Yang XL, Zhou Y, Fox H, Xiong H: **Direct contacts of microglia on myelin sheath and Ranvier's node in the corpus callosum in rats.***J Biomed Res* 2018, **33**:192-200.
51. Halliday DWR, Gawryluk JR, Garcia-Barrera MA, MacDonald SWS: **White Matter Integrity Is Associated With Intraindividual Variability in Neuropsychological Test Performance in Healthy Older Adults.***Front Hum Neurosci* 2019, **13**:352.
52. Caso F, Agosta F, Filippi M: **Insights into White Matter Damage in Alzheimer's Disease: From Postmortem to in vivo Diffusion Tensor MRI Studies.***Neurodegener Dis* 2016, **16**:26-33.
53. Delli Pizzi S, Franciotti R, Taylor JP, Esposito R, Tartaro A, Thomas A, Onofri M, Bonanni L: **Structural Connectivity is Differently Altered in Dementia with Lewy Body and Alzheimer's Disease.***Front Aging*

*Neurosci* 2015, **7**:208.

54. Chiang PL, Chen HL, Lu CH, Chen PC, Chen MH, Yang IH, Tsai NW, Lin WC: **White matter damage and systemic inflammation in Parkinson's disease.***BMC Neurosci* 2017, **18**:48.
55. Lenfeldt N, Holmlund H, Larsson A, Birgander R, Forsgren L: **Frontal white matter injuries predestine gait difficulties in Parkinson's disease.***Acta Neurol Scand* 2016, **134**:210-218.
56. Ackermann C, van Toorn R, Andronikou S: **Human immunodeficiency virus-related cerebral white matter disease in children.***Pediatr Radiol* 2019, **49**:652-662.
57. Zhu T, Zhong J, Hu R, Tivarus M, Ekholm S, Harezlak J, Ombao H, Navia B, Cohen R, Schifitto G: **Patterns of white matter injury in HIV infection after partial immune reconstitution: a DTI tract-based spatial statistics study.***J Neurovirol* 2013, **19**:10-23.
58. Li RL, Sun J, Tang ZC, Zhang JJ, Li HJ: **Axonal chronic injury in treatment-naive HIV+ adults with asymptomatic neurocognitive impairment and its relationship with clinical variables and cognitive status.***BMC Neurol* 2018, **18**:66.

## Figures




Figure 1

Interruption of white matter linear integrity by system LPS, obviously reversed by Minocycline. A, FA and MD values were measured and analyzed on regions of the interest in the rostral (red frame) and middle (green frame) part of the CC body. B, the FA values, namely linear movements of water molecules paralleling with the axons, was significantly distorted by system LPS (N = 8 in both Saline and LPS groups;  $p < 0.05$ , shown as \*); while, minocycline reversed this distortion to an approximately significant level (N = 8 in both LPS and LPS + Minocycline groups;  $p = 0.0657$ ). C, the MD values, namely water

diffusion with angles to the axons, was enhanced to an almost significant level comparing to the Saline group ( $p = 0.0570$ ); however, co-delivery of minocycline seemed to invert this effect.





Figure 2


Declination of CC nerve fibers CAP by system LPS and inverted by Minocycline. A, LPS highly significantly downshifted the I/O curve of CC fibers CAP, revealed by AUC (areas under the curves) measurement and analysis, comparing to the I/O curve constructed in Saline group (N = 4 in both Saline

and LPS groups;  $p < 0.01$ , shown as \*\*). B, minocycline significantly reversed the system LPS induced CAP declination also indicated by comparison of AUC between groups (N = 4 in both Saline and LPS groups, N = 8 at LPS + Minocycline cases;  $p < 0.05$ , shown as \*), suggesting a prevention of minocycline for white matter tract from system LPS induced malfunction.



**Figure 3**


System LPS induced increment of  $\beta\text{-APP}$ , iNOS and TNF- $\alpha$ , and minocycline inhibited their protein upgrading. A, accumulation of  $\beta\text{-APP}$  in the CC tissue reflected by highly significantly higher level of protein in LPS group than that in Saline group (N = 4;  $p < 0.01$ , shown as \*\*). Minocycline evidently reversed this accumulation but not reach to a significant level. B, iNOS density in the CC of LPS group was highly significantly enhanced comparing to that in Saline group (N = 4;  $p < 0.01$ , shown as \*\*); well, minocycline significantly reversed high level of iNOS evoked by system LPS (N = 4;  $p < 0.05$ , shown as \*). C, similarly, the CC TNF- $\alpha$  level in LPS group was significantly higher than that in Saline cases (N = 4;  $p < 0.05$ , shown as \*); while, minocycline significantly inhibited TNF- $\alpha$  upgrading (N = 4;  $p < 0.05$ , shown as \*).



**Figure 4**

Activation of microglia by system LPS, attenuated by Minocycline. A, resting microglia with thin somata and delicate pseudopodia were observed in the CC of Saline group as shown in the inset. B, majority of Iba-1 positive microglia in LPS treated CC were hyper-ramified with hypertrophic somata or showing amoeba like morphology as viewed in the inset. C, hypertrophic somata and/or pseudopodia were also viewed in minocycline co-injected group (see the inset); whereas, amoeba like microglia was almost

vanished. D, statistical processing of proportional area data displays that system LPS has highly significantly expanded proportional area (N = 3 in both Saline and LPS groups;  $p < 0.01$ , shown as \*\*); while, minocycline significantly reversed proportional area values comparing to that in LPS group (N = 6 in LPS + Minocycline cases;  $p < 0.05$ , shown as \*). Scale bars in A-C are 50  $\mu\text{m}$ .



**Figure 5**

In situ measurement of MBP and NF protein densities showed no significant change. A-C, MBP immunostained myelinated nerve fibers in Saline cases (A), LPS group (B) and LPS + Minocycline animals (C). D, statistical comparison of measured MBP immunofluorescence intensity exhibits no apparent difference between Saline, LPS and LPS + Minocycline groups (N = 3 in Saline and LPS groups, N = 4 in LPS + Minocycline rats). E-G, NF immunoreactivity of CC nerve fibers in Saline (E), system LPS (F) and LPS + Minocycline groups (G). H, statistical process of measured NF immunofluorescence intensity shows no significant difference between 3 groups (N = 3 in Saline and LPS groups, N = 4 in LPS + Minocycline rats); however, NF intensity of immunofluorescent labeling in the LPS group was obviously lower than that in the Saline and LPS + Minocycline groups. Scale bars for A-C and E-G are 50  $\mu\text{m}$ .